Skip to content
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Hematology · Myeloid/Lymphoid Neoplasm with JAK2 Rearrangement

Understanding Your Diagnosis: MLN with JAK2 Rearrangement

At a Glance

This rare blood cancer is driven by a JAK2 gene fusion that can affect myeloid or lymphoid blood cells. The disease may be chronic or acute, so identifying the fusion and working with hematology specialists helps guide individualized treatment.

Receiving a diagnosis of a myeloid/lymphoid neoplasm (MLN) with a JAK2 rearrangement means you are facing an exceptionally rare blood cancer. Because it is so uncommon, many local hematologists may never have seen a case in their entire careers [1]. This can make the diagnosis feel isolating, but it also means that your care should be guided by the most up-to-date genetic understanding of the disease.

Understanding the Name

The name of your diagnosis describes two main things: where the cancer is located and the specific genetic “glitch” driving it.

  • Myeloid/lymphoid neoplasm: This tells you the cancer involves the blood-forming cells in your bone marrow. “Myeloid” and “lymphoid” are the two main “branches” of the blood cell family tree [2]. The neoplasm may involve myeloid and/or lymphoid lineages and can sometimes develop a myeloid or lymphoblastic blast phase [3]. Classification requires integrated clinical and molecular assessment.
  • JAK2 rearrangement: This is the genetic driver. A rearrangement happens when a piece of a chromosome undergoes a structural change (like a translocation, inversion, or deletion). In your case, the JAK2 gene has fused with another partner gene (such as PCM1, ETV6, or BCR) [4][5].

What is a Tyrosine Kinase Gene Fusion?

When two genes fuse together, they create a tyrosine kinase gene fusion. You can think of a tyrosine kinase like a biological “on/off” switch for cell growth [6].

Under normal circumstances, the JAK2 switch only turns “on” when your body needs more blood cells. However, when it is fused to another gene, the switch gets stuck in the “on” position [7]. This sends a constant, uncontrolled signal to your bone marrow to alter cell production, which eventually leads to cancer [4].

Why This Diagnosis is Unique

This condition is classified as a “fusion-defined” neoplasm. In the past, doctors grouped blood cancers based only on how the cells looked under a microscope. Today, major international organizations like the World Health Organization (WHO) and the International Consensus Classification (ICC) group this disease based on the JAK2 genetic rearrangement itself [5][8].

Key characteristics include:

  • Extreme Rarity: There is no official population-wide count of how many people have this disease because it is so rare. Most of what doctors know comes from small “case series” (reports on small groups of patients) rather than large clinical trials [9][10].
  • Variable Presentations: It can present as a chronic phase (often appearing like a Myeloproliferative Neoplasm or MDS), where blood counts are abnormal but the disease moves slowly [11]. It can also present as, or transform into, an acute phase (like leukemia), which is more aggressive and requires more intensive treatment [2][3].
  • Eosinophilia: Many patients have high levels of eosinophils (a type of white blood cell), though this is not true for everyone [2].

Navigating the Emotional Journey

Finding out you have a disease that many doctors haven’t heard of can be overwhelming. It is common to feel a sense of “diagnostic uncertainty” or isolation [12][13]. Research shows that patients with rare blood cancers often face a heavy emotional burden, including anxiety about the future and the need for more specialized information [14][15].

Because the disease is so complex, treatment is highly individualized. Specialists often look toward targeted therapies—drugs designed to block the stuck JAK2 switch—and may discuss a stem cell transplant as a potential long-term curative option [11][16].

Seeking Specialized Care

Because of its rarity, “best practices” for this disease are still being refined by global experts [16]. Many patients find it helpful to be seen at an academic medical center or a “Center of Excellence” where hematologists specialize in rare genetic blood disorders, often sharing care with a local doctor. These centers are more likely to have the advanced genetic testing (like RNA sequencing) needed to identify the JAK2 fusion precisely [2][17].

Common questions in this guide

What does a myeloid/lymphoid neoplasm with JAK2 rearrangement mean?
It is a very rare blood cancer involving blood-forming cells in the bone marrow. The JAK2 gene has joined with another gene, creating an abnormal growth signal that can affect myeloid and/or lymphoid blood-cell lineages.
How can I find out which gene is fused to JAK2?
The partner gene may be PCM1, ETV6, BCR, or another gene. Molecular test results and, when needed, RNA sequencing can identify the exact fusion, which your hematologist can explain in the context of your diagnosis.
Does JAK2-rearranged MLN always become acute leukemia?
No. It may present in a slower chronic phase that resembles an MPN or MDS, or it may present as or change into an acute phase resembling leukemia. The phase and other clinical and molecular findings help specialists plan monitoring and treatment.
Why should I see a specialist or academic medical center?
This condition is exceptionally rare, so a center experienced with rare blood cancers may offer specialized expertise and advanced fusion testing. Care can sometimes be shared between an academic center and your local hematologist.
What treatments may be considered for MLN with JAK2 rearrangement?
Treatment is individualized because the disease can have different blood-cell patterns and phases. Doctors may discuss targeted drugs that block the abnormal JAK2 signal and may consider a stem cell transplant as a potential long-term treatment.
What is eosinophilia, and does everyone with this diagnosis have it?
Eosinophilia means having higher-than-normal levels of eosinophils, a type of white blood cell. It is common in this condition but does not occur in every patient.

Get notified when new evidence is published on Myeloid/lymphoid neoplasm associated with JAK2 rearrangement.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (17)
  1. 1

    Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: reevaluation of the defining characteristics in a registry-based cohort.

    Metzgeroth G, Steiner L, Naumann N, et al.

    Leukemia 2023; (37(9)):1860-1867 doi:10.1038/s41375-023-01958-1.

    PMID: 37454239
  2. 2

    How I diagnose and treat myeloid/lymphoid neoplasms with tyrosine kinase gene fusions.

    Reiter A, Metzgeroth G, Cross NCP

    Blood 2025; (145(16)):1758-1768 doi:10.1182/blood.2023022417.

    PMID: 39046810
  3. 3

    T cell phenotype and lack of eosinophilia are not uncommon in extramedullary myeloid/lymphoid neoplasms with ETV6::FLT3 fusion: a case report and review of the literature.

    Schoelinck J, Gervasoni J, Guillermin Y, et al.

    Virchows Archiv : an international journal of pathology 2024; (484(5)):853-857 doi:10.1007/s00428-023-03693-5.

    PMID: 37985498
  4. 4

    Integrated genomic analysis using chromosomal microarray, fluorescence in situ hybridization and mate pair analyses: Characterization of a cryptic t(9;22)(p24.1;q11.2)/BCR-JAK2 in myeloid/lymphoid neoplasm with eosinophilia.

    Snider JS, Znoyko I, Lindsey KG, et al.

    Cancer genetics 2020; (246-247()):44-47 doi:10.1016/j.cancergen.2020.08.004.

    PMID: 32827877
  5. 5

    Updates on eosinophilic disorders.

    Tzankov A, Reichard KK, Hasserjian RP, et al.

    Virchows Archiv : an international journal of pathology 2023; (482(1)):85-97 doi:10.1007/s00428-022-03402-8.

    PMID: 36068374
  6. 6

    Long read nanopore DNA sequencing with adaptive sampling to identify tyrosine kinase fusion genes.

    Salmon M, Naumann N, Rinke J, et al.

    Leukemia 2026; (40(1)):37-46 doi:10.1038/s41375-025-02801-5.

    PMID: 41254115
  7. 7

    Myeloid neoplasms with eosinophilia.

    Reiter A, Gotlib J

    Blood 2017; (129(6)):704-714 doi:10.1182/blood-2016-10-695973.

    PMID: 28028030
  8. 8

    The international consensus classification of eosinophilic disorders and systemic mastocytosis.

    Wang SA, Orazi A, Gotlib J, et al.

    American journal of hematology 2023; (98(8)):1286-1306 doi:10.1002/ajh.26966.

    PMID: 37283522
  9. 9

    Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter study.

    Tang G, Sydney Sir Philip JK, Weinberg O, et al.

    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2019; (32(4)):490-498 doi:10.1038/s41379-018-0165-9.

    PMID: 30401948
  10. 10

    Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors among Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusion.

    Zhang Y, Nguyen L, Lu CM, et al.

    Clinical lymphoma, myeloma & leukemia 2023; (23(3)):e150-e163 doi:10.1016/j.clml.2022.12.008.

    PMID: 36624015
  11. 11

    PCM1-JAK2 Fusion Tyrosine Kinase Gene-Related Neoplasia: A Systematic Review of the Clinical Literature.

    Kaplan HG, Jin R, Bifulco CB, et al.

    The oncologist 2022; (27(8)):e661-e670 doi:10.1093/oncolo/oyac072.

    PMID: 35472244
  12. 12

    [Myeloid/lymphoid neoplasms with eosinophilia and FGFR1 rearrangement: 5 cases report and literatures review].

    Liu YT, Zhao JW, Feng J, et al.

    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2019; (40(10)):848-852 doi:10.3760/cma.j.issn.0253-2727.2019.10.010.

    PMID: 31775485
  13. 13

    Social Media and Internet Resources for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).

    Pemmaraju N, Gupta V, Thompson MA, Lane AA

    Current hematologic malignancy reports 2016; (11(6)):462-467 doi:10.1007/s11899-016-0340-3.

    PMID: 27492117
  14. 14

    A scale for patient-reported symptom assessment for patients with Erdheim-Chester disease.

    Diamond EL, Reiner AS, Buthorn JJ, et al.

    Blood advances 2019; (3(7)):934-938 doi:10.1182/bloodadvances.2018030502.

    PMID: 30917949
  15. 15

    Myeloproliferative neoplasm questionnaire: assessing patient disease knowledge in the modern digital information era.

    Pemmaraju N, Wilson NR, Clementi Doan T, et al.

    Leukemia & lymphoma 2021; (62(9)):2253-2260 doi:10.1080/10428194.2021.1901096.

    PMID: 33749512
  16. 16

    Role of allo-HCT in "nonclassical" MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT.

    Polverelli N, Hernández-Boluda JC, Onida F, et al.

    Blood 2025; (145(22)):2561-2573 doi:10.1182/blood.2024028000.

    PMID: 40106773
  17. 17

    Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase fusion genes: A workshop report with focus on novel entities and a literature review including paediatric cases.

    Saft L, Kvasnicka HM, Boudova L, et al.

    Histopathology 2023; (83(6)):829-849 doi:10.1111/his.15021.

    PMID: 37551450

This page is for informational purposes only and does not constitute medical advice about MLN with a JAK2 rearrangement. Your hematologist and specialized care team should interpret your fusion results and discuss treatment options with you.